Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW; COV-BARRIER Study Group.
.
.
Item in Clipboard
. Dagan N, et al.Nat Med. 2021 Sep 7. doi: 10.1038/s41591-021-01490-8. Online ahead of print.Nat Med. 2021.PMID: 34493859
.
.
Item in Clipboard
Estimation of the Total Number of SARS-CoV-2-infected Individuals and the Necessary Tests and Cost during the First Wave of the COVID-19 Pandemic in Japan.
![top](data:image/svg+xml,%3Csvg%20xmlns="http://www.w3.org/2000/svg"%20width="16"%20height="16"%3E%3Crect%20fill-opacity="0"/%3E%3C/svg%3E "top")
